ATG9A and in situ carcinoma: Moreover, significantly higher concentrations of ATG9A were identified in the kidneys of the CIS-treated Gal-3 KO mice compared to the CIS-treated Gal-3 wild-type mice, with statistical significance (p < 0.001) (Figure 10D).